[Present-day aminoglycosides in the treatment of suppurative-septic diseases].
The therapeutic efficacy, tolerance and pharmacokinetics of sisomicin, gentamicin and a new dosage form of kanamycin sulfate as an ampoule solution for intravenous injection were studied clinically. High therapeutic efficacy of the above three aminoglycosides in the treatment of severe inflammatory infections caused by gram-negative bacteria was shown with the use of the adequate doses. Favourable results of the therapy estimated by the laboratory and clinical data were observed in 81-90 per cent of the patients.
D000328:Adult; D000617:Aminoglycosides / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D001424:Bacterial Infections / Q000188:drug therapy*; D002648:Child; D002986:Clinical Trials as Topic; D004352:Drug Resistance, Microbial; D004755:Enterobacteriaceae / Q000187:drug effects; D005839:Gentamicins / Q000627:therapeutic use; D006801:Humans; D007612:Kanamycin / Q000627:therapeutic use; D011550:Pseudomonas aeruginosa / Q000187:drug effects; D012853:Sisomicin / Q000627:therapeutic use; D013211:Staphylococcus aureus / Q000187:drug effects; D013492:Suppuration
D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D005839:Gentamicins; D007612:Kanamycin; D012853:Sisomicin
Sovremennye aminoglikozidy v lechenii gnoĭno-septicheskikh zabolevaniĭ.